Redenlab contributes to position paper on advancing digital healthtechnologies for frontotemporal degeneration
MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap…
neurodegenerative
Latest content
Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research
Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research
Redenlab’s Chief Science Officer, Adam P. Vogel, PhD, leads groundbreaking study on speech analysis for neurodegenerative diseases
MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a…
Redenlab strengthens its reach in linguistic/language analytics with appointment of eminent neuroscientist Prof Adolfo Garcia
Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal…
SpeechATAXIA- a multinational, multilanguage consortia for speech in hereditary ataxias – powered by Redenlab
SpeechATAXIA is a multi-language, multi-national, multi-ataxia consortia designed to measure communication change over time.
Redenlab supporting new randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Redenlab is supporting a new long term open label extension study in Friedreich ataxia
Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics…
Redenlab chosen for new multinational natural history study in Dentatorubral-pallidoluysian atrophy (DRPLA)
Redenlab Inc, the speech neuroscience company delivering insights in communication testing, announces that it has been selected by…
Redenlab supporting PTC Theraputics in Global Phase 3 Clinical Trial
Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in…
Redenlab joins global Friedreich ataxia collaboration
Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe…
